Clinical Trials Logo

Overweight clinical trials

View clinical trials related to Overweight.

Filter by:

NCT ID: NCT03550248 Completed - Clinical trials for Overweight and Obesity

Healthy Together Program Evaluation (Phase 3)

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

Healthy Together is a program that promotes the achievement and maintenance of healthy weights in children and their families.

NCT ID: NCT03548987 Completed - Obesity Clinical Trials

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

STEP 4
Start date: June 4, 2018
Phase: Phase 3
Study type: Interventional

This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what a participant can do to lose weight. The participant will get semaglutide for the first 20 weeks. Then the participant will get either semaglutide or "dummy" medicine - which treatment the participant gets after the 20 weeks is decided by chance. The participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years.

NCT ID: NCT03548935 Completed - Clinical trials for Overweight or Obesity

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

STEP 1
Start date: June 4, 2018
Phase: Phase 3
Study type: Interventional

This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what you can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment participants get, is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study has two phases: A main phase and an extension phase.The main phase will last for about 1.5 years. Participants will have 15 clinic visits and 10 phone calls with the study doctor. Extension phase: Approximately 300 participants will continue in the extension phase in the following countries only: Canada, Germany, the UK and selected sites in the US and Japan. These participants will be in the study for about 2.5 years.They will not receive treatment, but will attend another 5 follow-up visits with the study doctor.

NCT ID: NCT03547453 Completed - Clinical trials for Overweight and Obesity

Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome

Start date: June 4, 2018
Phase:
Study type: Observational

The investigators would like to determine how aspects of adiposity and age influence ultrasound features of the ovaries which are used to diagnose polycystic ovarian syndrome (PCOS). The study will also compare anti-Müllerian hormone (AMH) levels against ultrasound features of the ovary to predict PCOS.

NCT ID: NCT03546972 Active, not recruiting - Obesity Clinical Trials

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

Start date: December 17, 2017
Phase: N/A
Study type: Interventional

This pilot trial studies how well a diabetes prevention program with or without hunger training works in helping to lower breast cancer risk in obese participants. A diabetes prevention program involves learning about and receiving materials on different strategies to encourage weight loss, and hunger training involves learning how to recognize hunger. It is not yet known whether adding hunger training to a diabetes prevention program helps participants control their weight that could reduce the risk of some cancers.

NCT ID: NCT03545360 Recruiting - Obesity Clinical Trials

Safety and Efficacy of the BTL-703 Treatment for the Non-invasive Lipolysis

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The study will evaluate safety and efficacy of the BTL-703 device for the non-invasive lipolysis.

NCT ID: NCT03543644 Completed - Healthy Clinical Trials

Strategies To OPpose Sugars With Non-nutritive Sweeteners Or Water (STOP Sugars NOW) Trial

Start date: May 31, 2018
Phase: N/A
Study type: Interventional

Health authorities recommend a reduction in added sugars from sugar-sweetened beverages (SSBs) due to risk of obesity and diabetes. As a sugar-reduction strategy, finding the ideal SSB replacement is of the utmost importance. Those who are already consuming SSBs might not easily replace it with water and therefore non-nutritive sweetened beverages (NSBs) present a sweetened alternative, though guidelines recommend water instead of NSBs as a replacement for SSBs. Recent evidence suggests that saccharine, a non-nutritive sweetener, which is not found in NSBs, might induce glucose intolerance by altering gut microbiota in humans. It is currently not known if replacing SSBs with NSBs (which contain low-calorie sweeteners other than saccharine) or water will have any effect on the human gut microbiota and any downstream diabetic risk. The investigators plan to undertake a randomized controlled cross-over trial in 75 healthy adults to assess the effect of replacing SSBs with equal amounts of NSBs or water for 4 weeks on the composition and diversity of human gut microbiota, changes in glucose tolerance and total body fat in those who regularly drink SSBs. Each participant will act as their own control receiving each of the three interventions of SSB, NSB and water for four weeks in random order, each period separated by a four-week wash-out period. All study visits will occur at the Clinical Nutrition and Risk Factor Modification Centre at St. Michael's Hospital. This study will contribute to knowledge that will inform dietary guidelines and public policy with regards to the best possible replacement for SSBs. It will also shed light on the potential mechanism of the adverse effects of NSBs and if the replacement of SSBs by NSBs or water are in fact similar with respect to their effect on gut bacteria and any downstream diabetic risk.

NCT ID: NCT03542864 Completed - Obesity Clinical Trials

Medical Supervised Duodenal-Enteral Feeding Treatment

Start date: August 3, 2017
Phase: N/A
Study type: Interventional

Medical Supervised Duodenal-Enteral Feeding for Overweight, Obesity and Increased Body Fat Percentage Treatment based on an intervention procedure performed by a Licensed Nutritionist Doctor for weight loss and loss of fat percentage in patients who need it.

NCT ID: NCT03542604 Completed - Breast Cancer Clinical Trials

Cancer, Obesity/Overweight and Insomnia Study

COIN
Start date: June 12, 2018
Phase: N/A
Study type: Interventional

This is a randomized pilot study to better understand the relationships among insomnia, weight loss, and breast cancer. This study will assess the effectiveness of a sleep intervention prior to a web- and phone-based weight loss program.

NCT ID: NCT03541005 Completed - Clinical trials for Overweight and Obesity

Evaluation of Obex® in Overweight and Obesity

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

- Obesity is an important and growing worldwide - Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer - Diverse adverse events have been reported with the use of antiobesity drugs. - Several articles describe the beneficial effect of several specific components of the Obex® supplement on weight loss, in the reduction of waist circumference, suppression of appetite, decrease fasting glucose levels, improvement of insulin sensitivity and β cells function. - Therefore, the administration of Obex in overweight and obese patients could be an excellent strategy to induce weight loss and ameliorate the metabolic disturbances related to obesity and overweight.